IL2-CD25 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Autoimmune Disorders.

(Nivolumab + relatlimab) is under clinical development by Bristol-Myers Squibb and currently in Phase III for Non-Small Cell Lung Cancer.

Argyle have drawn three and lost six of their last nine fixtures and sit bottom of the Championship table, four points from ...

BRISTOL, Va. (WDBJ) - Fire crews were called back to the former Virginia Intermont College campus in Bristol this past ...

We recently compiled a list of the Long-Term Stock Portfolio: Best Stocks for 10 Years. In this article, we are going to take ...

Emotional’ director of rugby irked by doubters following Sharks’ best performance of the season against Bristol ...

Palmer has predicted that a defeat to Bristol City in their next game could spell the end of Rooney’s time with Plymouth.

Harry Byrne is on the cusp of signing a three-month loan deal with Bristol Bears and could make his debut for the Premiership ...

Daryl Jacob called time on 25-year career after steering Impaire Et Passe to Grade One victory at Limerick on Saturday; Jacob lifted the 2012 Grand National with Neptune Collonges; 41-year-old rode ...

Bristol has been named in the top ten venues for a stag do in Europe - and is now above Amsterdam and Krakow. And according ...

A community centre has been cooking up free breakfasts to help combat loneliness and poverty over the festive period. The ...

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...